Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
Technology appraisal guidance
Reference number: TA1015
Published:
This appraisal is expected to start during early October 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during mid-November 2023.